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Abstract
Alcoholic liver disease (ALD) is a leading cause of liver related mortality worldwide. In contrast 
to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant 
lack of novel therapeutic options for patients with ALD. In particular, there is an urgent need to 
focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most 
severe form of ALD. AH is characterized by an abrupt development of jaundice and complications 
related to liver insufficiency and portal hypertension in patients with heavy alcohol intake. The 
mortality of patients with AH is very high (20–50% at 3 months). Available therapies are not 
effective in many patients and targeted approaches are imminently needed. The development of 
such therapies requires translational studies in human samples and suitable animal models that 
reproduce clinical and histological features of AH. In recent years, new animal models that 
simulate some of the features of human AH have been developed, and translational studies using 
human samples have identified potential pathogenic factors and histological parameters that 
predict survival. This review article summarizes the unmet needs for translational studies on the 
pathogenesis of AH, pre-clinical translational tools, and emerging drug targets to benefit the AH 
patient.
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The global morbidity and mortality of alcoholic liver disease (ALD) are associated with 
alcohol abuse over prolonged periods. Recent epidemiologic studies show that liver cirrhosis 
is the 12th leading cause of death and approximately 50% of the total fatalities are alcohol-
related (NIAAA Surveillance report #100). ALD encompasses different stages as a 
consequence of susceptibility factors, duration and intensity of alcohol consumption. Some 
of the histological stages can co-exist and include steatosis, alcoholic steatohepatitis (ASH) 
and progressive fibrosis to cirrhosis and superimposed hepatocellular carcinoma (HCC). 
Moreover, patients with underlying ALD and heavy alcohol intake can develop a form of 
acute-on-chronic liver injury called alcoholic hepatitis (AH). Severe AH has very high short-
term mortality (20–50% at 3 months) and represents one of the deadliest diseases in clinical 
hepatology.1 Despite its economical and health burden, ALD has received very limited 
attention from health policy makers, pharmaceutical companies, and private funding 
agencies. While research has made significant progress, the pathogenesis of ALD remains 
incompletely understood and there is little or no impact on development of new therapies. 
Limitations in patient characterization due to poor diagnostic and prognostic measures, 
inadequate models of disease and insufficient pre-clinical/translational approaches, have 
stunted the progress in the field of ALD. One of the most urgent needs in this field is to 
identify new targeted therapies for patients with AH. This need is further confirmed by the 
recent STOPAH trial that showed limited efficacy of prednisolone.2 In this article, we review 
the molecular pathogenesis of AH and highlight translational studies that might lead to 
targeted approaches for the treatment of AH. Discussion of entry criteria and end-points for 
clinical trials is beyond the scope of this review.
Alcoholic hepatitis: clinical aspects and unmet needs
Until it reaches advanced stages, ALD is mostly asymptomatic. Patients with prolonged 
alcohol misuse develop steatosis and signs of hepatocellular damage (ballooning and 
Mallory-Denk bodies) and inflammatory infiltrate (typically neutrophils), which define 
ASH. ASH is a histological concept that can be present both in subclinical patients (defined 
as subclinical ASH) and in patients with significant clinical syndrome (defined as AH). 
Patients with subclinical ASH can be asymptomatic for prolonged periods of time (fully 
compensated and preserved hepatic function).1,3 This subclinical stage of disease is poorly 
characterized in humans and there is an unmet need to delineate its natural history and 
prognostic factors as well as to develop non-invasive markers. Eventually, a proportion of 
patients with subclinical ASH may develop cirrhosis (8–20%), which confers a high risk of 
complications. Some patients with ASH can also present a form of acute-on-chronic liver 
failure called AH, which often occurs after recent excessive alcohol binge drinking.1 AH is 
characterized by an abrupt rise in serum bilirubin levels, jaundice, coagulopathy, and liver-
related complications. Traditionally, it was thought that AH could occur in patients with 
mild underlying ALD. However, more recent studies using tru-cut needles to obtain liver 
biopsy reveal that the vast majority of patients with AH have underlying cirrhosis.4 In some 
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patients, the episode of AH may occur as the first manifestation in patients who have 
experienced silent ALD, while in others it is an exacerbation of pre-existing alcoholic 
cirrhosis. Therefore, AH should be distinguished from subclinical ASH in fully compensated 
patients (Figure 1).
Importantly, patients with ALD can present an episode of jaundice and liver decompensation 
for reasons other than superimposed AH. These conditions include severe sepsis, biliary 
obstruction, diffuse HCC, drug-induced liver injury and ischemic hepatitis (i.e, due to 
massive bleeding or cocaine use). Therefore, not all episodes of jaundice in patients with 
underlying ALD should be attributable to AH. In patients with other potential causes of 
jaundice, with severe forms of ALD, or involved in clinical trials, a transjugular liver biopsy 
is recommended to confirm the existence of AH.5, 6 Future studies including clarification of 
the nomenclature to define subclinical ASH as well as moderate and severe AH are needed 
to further understand the heterogeneity and stages of human ALD.
The incidence of AH is not well known and it is likely that many cases are undiagnosed. 
Population based studies estimate approximately 4.5 hospitalizations for AH per 100,000 
persons each year, with a slight male predominance in Western countries.7 AH patients, 
typically present with symptoms, such as rapidly progressive jaundice, which can be 
accompanied by fever, abdominal pain, anorexia, and weight loss. There are several clinical 
scoring systems to assess the severity of AH: Maddrey’s discriminant function-DF-, MELD, 
ABIC and Glasgow.4, 8, 9 Among them, Maddrey’s DF is the most widely used. Short-term 
mortality in patients with severe AH is due to sepsis, liver failure and multi-organ 
dysfunction.10 Moreover, a recent multi-centric study developed a histological scoring 
system capable of predicting short-term survival in patients with AH.4 The resulting 
Alcoholic Hepatitis Histological Score (AHHS) comprises 4 parameters that are 
independently associated with patients’ survival: fibrosis stage, neutrophil infiltration, type 
of bilirubinostasis, and presence of megamitochondria. By combining these parameters in a 
semiquantitative manner, patients can be stratified into low, intermediate, or high risk for 
death within 90 days.4
The management of patients with AH has not evolved substantially over the last decades. In 
severe AH (e.g. poor mental status or hypotension), patients may need admission to an 
intensive care unit. Prevention of alcohol withdrawal symptoms and Wernicke’s 
encephalopathy are recommended. Daily protein intake of 1.5 g/kg body weight is also 
advised. Because patients with AH are predisposed to severe infections, which may threaten 
survival, early diagnosis and empiric antibiotic treatment are advised. On discharge, patients 
should follow alcohol counseling to reach sustained abstinence, a major determinant of long-
term survival.11 In addition to these general measures, pharmacological therapy with 
prednisolone for 4 weeks has been shown to improve short-term survival in patients with 
severe AH. The efficacy of pentoxifylline is still questionable.1, 2, 12 A recent study has 
shown some beneficial effects of N-acetylcysteine, a potent but cell-impermeant 
antioxidant.13 Unfortunately, many patients do not respond to prednisolone, thus novel 
targeted therapies are urgently needed. Recently, liver transplantation, in highly selected AH 
patients, is shown to improve survival significantly,14 but a number of clinical and ethical 
considerations, particularly recidivism, limit eligibility. Furthermore, the relative shortage of 
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donor organs adds to the ethical challenges before consideration of patients for liver 
transplant.
There are several important unmet needs in diagnosis, management and therapy of AH.15 
First, patients often present in the emergency room with very advanced disease, severe sepsis 
and poor physical status, having high mortality within few days. Informative campaigns in 
primary care centers, addiction centers and in the general population about the clinical 
relevance of jaundice in patients with alcohol abuse should be emphasized. Second, the 
specific mechanisms, outcome, and responses to therapy of the most common secondary 
complications (encephalopathy, infections, renal failure, etc) are largely unknown. There are 
only few studies characterizing these complications in this particular population and 
additional studies to understand their underlying mechanisms are warranted.16, 17 Third, the 
extra-hepatic consequences of AH that lead to multi-organ dysfunction and death are not 
well defined. The existence of systemic inflammatory response syndrome (SIRS) is a major 
predictor of acute organ failure in these patients, suggesting that the extra-hepatic 
consequences of AH play a major role on disease severity.10, 17 Finally, a meaningful 
molecular classification of these patients could guide the use of targeted therapies. Not all 
patients are seen at the same stage of the disease. It is likely that different types and patterns 
of hepatic inflammation play defining roles for subclinical ASH, moderate and severe AH; 
whereas impaired liver regeneration could be the major event in patients with severe AH. 
The development of a molecular classification for these patients is urgently needed and will 
certainly help in developing tailored therapies for these different spectra of the deadly 
disease.
Pathogenesis and molecular targets of AH
The cellular and molecular mechanisms of chronic ALD have been extensively studied in 
animal models over the last forty years. A wide variety of inflammatory mediators and their 
downstream signaling pathways, as well as several types of inflammatory cells have been 
identified to contribute to the pathogenesis of steatosis, hepatocellular damage, 
inflammation, and fibrosis in chronic ALD, which are summarized in several recent 
reviews.3, 18–21 In the current article, we mainly discuss the potential mechanisms initiated 
by persistent alcohol drinking causing liver failure as well as multi-organ failure in AH 
patients (Figure 2). In addition, potential molecular targets of AH are also discussed.
Most patients with underlying ALD develop AH after excessive and/or binge alcohol intake, 
suggesting that excessive binge drinking may contribute to development of AH. This notion 
is also supported by several recent studies from the chronic-plus-binge ethanol feeding 
model showing that acute ethanol binge markedly exacerbates liver injury and hepatic 
neutrophil infiltration in chronically ethanol-fed mice 22, 23 or in high-fat diet fed mice.24 
Moreover, recent efforts to recapitulate histologic and clinical features of AH in mice have 
resulted in the development of diffuse hepatic neutrophil infiltration, fibrosis, ductular 
reaction, splenomegaly, hypoalbuminemia, and hyperbilirubinemia.25 This model is based 
on intragastric feeding which assures heavy alcohol intake with sustained blood alcohol 
levels, the most important requirement for reproduction of AH patient behavior, and 
combination of common AH patient life-style factors such as Western diet and weekly binge 
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drinking.25 Interestingly, without weekly binge, this hybrid feeding model (intra-gastric and 
ad libitum feeding) produces chronic ASH with macrophage inflammation and liver fibrosis. 
When weekly binge is added, inflammation shifts to neutrophil infiltration, and histologic 
and clinical features of clinical AH ensue despite the same overall alcohol intake,25 further 
highlighting the critical role of binge drinking in inducing AH phenotype. At the present, 
how binge drinking initiates AH is not clear. It is likely that excessive binge drinking 
induces massive hepatocellular damage in patients with underlying chronic ALD who are 
prone to liver injury, and these damaged hepatocytes subsequently release a variety of 
damage-associated molecular patterns (DAMPs) to promote systemic inflammatory response 
syndrome (SIRS).20, 26
In addition to DAMPs, pathogen associated molecular patterns (PAMPs) likely also play an 
important role in inducing SIRS in AH patients. Chronic alcohol consumption is known to 
suppress antibacterial immune responses and increase bacterial infection, resulting in 
elevation of PAMPs in the liver and circulation.27 In addition, chronic alcohol intake induces 
gut dysbiosis and increases gut permeability, resulting in translocation of PAMPs such as 
lipopolysaccharide (LPS) into the portal circulation.28, 29 These elevated PAMPs then 
activate Kupffer cells and other inflammatory cells to produce a variety of pro-inflammatory 
cytokines such as TNFα, MCP-1 and IL-1β, which contribute to the pathogenesis of ALD.20 
Superimposing binge drinking aggravates gut permeability and bacterial and PAMP 
translocation, contributing to manifestation of SIRS 30 and multiple organ failure in 
alcoholics with underlying chronic ALD, resulting in AH (Figure 2).
So far, a large number of inflammatory mediators have been identified from the studies of 
animal models and human AH biopsies and some of them are listed in Table 1. Many of 
these inflammatory mediators are elevated as a consequence of PAMPs, bacterial 
translocation and severe hepatocellular damage in AH, and may further promote liver injury 
or deteriorate liver regeneration. Among these inflammatory mediators, TNFα has received 
the greatest attention in the early 1990s and shown to play a critical role in promoting liver 
injury in a rodent model of mild ALD.31 Consequently, TNFα-blocking agents were tested 
in patients with AH, albeit, with disappointing results due to the development of severe 
bacterial infections.32 This serves as an important lesson that TNFα has pleiotropic effects 
and that inflammation stimulated by TNFα or its downstream mediators may have protective 
anti-microbial and pro-regenerative roles that should be preserved. Later, a variety of 
chemokines including IL-8, CXCL-5, Gro-γ and CXCL-6, IL-1, osteopontin, MCP1/CCL2 
were found to be up-regulated, contributing to macrophage activation and neutrophil 
recruitment in AH, and in some cases correlating with AH patient survival.33–35 Another 
report identified molecular chaperone Hsp90, increased in AH, as a potential therapeutic 
target to modulate inflammatory responses.36 Activation of canonical inflammasome 
pathway, required for proteolytic cleavage of pro-IL-1β and pro-IL-18, is also implicated in 
experimental ALD,34, 37 and inhibition of IL-1 is currently under investigation for the 
treatment of AH patients.
Although the importance of liver resident macrophages (Kupffer cells) in chronic ALD is 
well documented, recent studies suggest that infiltrating macrophages derived from 
monocytes contribute to the pathogenesis of ASH.38 The migration of monocyte-derived 
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macrophages is dependent on Notch-1 and plays an important role in promoting M1 
macrophage inflammation in experimental sub-clinical ASH.39 However, the precise 
biologic or pathologic significance of resident vs. infiltrating macrophages during 
progression to AH or whether M1 macrophage activation is required for AH is still unclear. 
Neutrophil infiltration is a hallmark of sub-clinical ASH and is believed to induce 
hepatocellular damage and inflammation in AH. However, a recent study reported that 
infiltration of neutrophils is associated with better prognosis in AH, suggesting that 
neutrophils may also play beneficial roles in promoting liver repair and controlling bacterial 
infection in these patients.4 To this end, an ideal therapeutic agent may need to suppress the 
release of cytotoxic mediators by neutrophils while preserving their efficient bacterial killing 
properties.40
In addition to inflammation, poor hepatic regenerative response is probably another 
important mechanism contributing to the liver failure in some AH patients. A detailed 
analysis of liver explants from AH patients that underwent liver transplantation revealed that 
patients who failed to respond to medical therapy had reduced hepatic expression of liver 
regeneration-related cytokines and the lack of proliferative hepatocytes.41 This observation 
was further confirmed by another study, which showed that presence of proliferating 
hepatocytes in AH is associated with a better prognosis.42 In addition, a massive expansion 
of liver progenitor cells (LPCs) called “ductular reaction” is often observed in AH patients, 
but these LPCs fail to differentiate into mature hepatocytes and correlate positively with 
severity of liver disease and short-term mortality in these patients.43 At present, the 
mechanisms leading to inefficient liver regeneration in AH are unknown and deserve further 
investigation. In addition, the treatment of AH patients with steroids may further block liver 
regeneration in these patients because steroids suppress inflammation and subsequently 
inflammation-mediated liver regeneration.44
In summary, in overt AH patients, a large number of inflammatory mediators are activated 
most likely contributing to SIRS, which together with impaired liver regeneration causes 
liver failure and multiple organ failure (Figure 2). These inflammatory mediators 
cooperatively promote liver inflammation and injury in AH. Thus it may be difficult to 
demonstrate clinical efficacy for the treatment of AH by targeting a single inflammatory 
mediator. Because many inflammatory mediators including TNFα also play an important 
roles in promoting liver regeneration, anti-inflammatory modalities for AH patients must 
preserve effective liver regeneration, and anti-inflammatory drugs may be combined with 
hepatoprotective agents. Indeed, a combination therapy with anti-inflammatory drugs (such 
as steroids) plus hepatoprotective drugs (such as interleukin-22) has been proposed and is 
currently under consideration for AH.45 In addition to inflammation and poor hepatic 
regenerative response, other challenges associated with AH patients include bacterial 
infections, hepatic encephalopathy, renal failure or hepatorenal syndrome, portal 
hypertension, ascites, and bleeding tendencies, and malnutrition. Those patients likely 
require combination therapies such as immunosuppressive drugs plus hepato- and renal-
protective drugs and anti-bacterial drugs.45 In AH, macrophages and T cells are often 
defective in their anti-bacterial functions,27 which in turn increase the risk of bacterial 
infection in these patients. Identifying new approaches to correct these defects and restore 
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normal immune responses, rather than to eliminate or suppress, appears a most logical and 
important future direction.
Translational approaches in AH: Human specimens and experimental 
models
The traditional approach to develop new targets for therapy in the field of AH consists of 
identifying molecular drivers in pre-clinical omics studies, in vitro and in vivo, that are 
ultimately tested in randomized clinical trials in patients (Figure 3). Early human studies 
identified molecular drivers such as TNFα and macrophage-derived ROS in AH 
patients.46, 47 Later studies in patients with AH using TNFα blocking agents and antioxidant 
cocktails were carried out with minimal positive outcomes.32, 48 Thus, a more rational 
approach would be to perform integrative “omics” studies in human samples from patients 
with AH and use pathway/network computational analysis to identify cellular and molecular 
mediators that correlate with disease outcome (i.e. short-term mortality or scoring systems 
that predict survival like Maddrey’s discriminant function-DF-, ABIC score, etc). Such 
studies could enable identification of disease-specific pathways, correlating expression or 
activation of molecular targets to clinical outcomes. Ideally, the functional role of such 
potential disease mediators should then be tested in preclinical models of overt “AH”. As 
discussed below in this article, while recent animal models of sub-clinical ASH offer some 
promise, they do not show all the features of overt AH (i.e. jaundice and cirrhosis). 
Developing a reliable model that closely reproduces the histological and clinical features of 
AH will advance this field. However, ALD is a disease of man and not animals, and the 
inherent anatomical and biological differences among the species likely dictate this gap, and 
development of a “true” AH model may be too idealistic. For this reason, subsequent studies 
testing plausible molecular targets in preclinical models should utilize them based on clear 
pathologic criteria. Since patients with AH are severely ill and have profound hepatic and 
renal dysfunctions, careful pharmacokinetic and pharmacodynamics studies as well as good 
laboratory practice (GLP) toxicology studies are mandatory. Moreover, as detailed later, 
phase I studies in healthy controls and ideally in patients with advanced liver disease are 
required before phase II trials can be carried out.
Human studies in patients with AH can be performed systematically using different types of 
biospecimens followed by correlation of function or expression of a molecule/pathway with 
the clinical outcome or phenotype (Figure 3). The first step consists of obtaining 
prospectively anthropometric, clinical, analytical and histological data. When a liver biopsy 
is not possible due to hemodynamic instability or unavailability in the research center, a 
precise clinical diagnosis should be established. In patients with confounding factors such as 
sepsis at admission, massive bleeding or hypotension, uncertain alcohol assessment or recent 
intake of hepatotoxic drugs, a liver biopsy is required to establish a proper diagnosis of AH. 
The second step is to define the phenotype of the patient; 1 and 3-month mortality rates are 
the most widely used parameters to define disease severity. Alternatively, existing scoring 
systems (i.e. Maddrey’s DF, ABIC or MELD) can be used to establish patient’s prognosis. 
Then, genetic signatures or the expression of genes or proteins found in human 
biospecimens can be correlated with clinical or histological features or patient outcome to 
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identify potential molecular drivers and/or pathways. The type of biospecimens that can be 
used for translational studies includes liver tissue (typically obtained through a transjugular 
approach), suprahepatic and peripheral blood (total blood, serum or plasma) and peripheral 
blood mononuclear cells (PBMCs) and neutrophils. These biospecimens can be used for 
genomic, proteomic or metabolomic studies. Due to increasing evidence that gut-derived 
bacterial products play a significant role in pathophysiology, collecting stools can be useful 
for translational studies in patients with AH. Overall, initiation of translational research 
should involve hypothesis-generating omics studies, in which disease-associated pathways 
or signatures linked to clinical outcome are identified. Key molecules of disease pathways 
should be further tested in pre-clinical in vivo and in vitro models to identify druggable 
molecular drivers. To overcome complexity of studies assessing different biological levels 
(i.e. DNA, RNA, proteins, metabolites), an integrative analysis by systems biology experts 
could further aid in understanding interdisciplinary complex interactions within biological 
systems of AH.
Over the last four decades, chronic ethanol feeding studies in rodents using either ad libitum 
or intragastric feeding models have significantly enhanced our understanding of the 
pathogenesis of ALD (Table 2). However, these models may produce some features of 
chronic ALD but not acute-on-chronic liver injury observed in AH patients. Recently, a new 
mouse model of chronic-plus-binge ethanol feeding was developed.23, 49 The feeding 
protocol in this model is similar to the drinking patterns of many AH patients: a history of 
chronic drinking superimposed by episodic excessive alcohol consumption. Chronic-plus-
binge ethanol feeding synergistically induced steatosis, liver injury, and hepatic neutrophil 
infiltration in mice,23, 49 which may be useful for the study of neutrophils and early stages of 
alcoholic liver injury in AH patients. Using this chronic-plus-binge alcohol model, 
researchers have begun to identify novel mechanisms that participate in the pathogenesis of 
alcoholic liver injury, thereby revealing novel therapeutic targets.22, 23, 36, 50, 51 However, 
hepatocellular damage and inflammation caused by chronic-plus-binge ethanol feeding are 
moderate and transient. 23, 49 Further, many AH patients are on Western diet and binge drink 
weekly on top of heavy daily alcohol intake, and it is important to study how alcohol 
drinking and obesity synergistically induce liver injury. Indeed, a single acute binge of 
ethanol induces acute steatohepatitis in high-fat diet-fed mice, resulting in steatohepatitis 
with neutrophil infiltration and liver fibrosis.24 However, these mouse models do not exhibit 
sustained high blood alcohol levels, which exemplify human alcoholics. To circumvent these 
weaknesses, a hybrid feeding model was developed by allowing ad lib feeding of solid 
Western diet at 40% of their caloric intake while assuring high alcohol intake and blood 
concentration by intragastric infusion of ethanol liquid diet at 60% calories.25 This model 
reproduces chronic ASH characterized by ballooned cell degeneration, macrophage 
activation and infiltration, and progression of liver fibrosis. Further, addition of weekly binge 
to the model produces diffuse neutrophil infiltration and ductular reaction similar to AH in 
patients, as well as clinical features of AH such as splenomegaly, hypoalbuminemia, and 
hyperbilirubinemia. However, this model has not achieved decompensation such as jaundice 
and ascites seen in severe AH although mild abdominal effusion and hyperbilirubinemia are 
noted.25 Thus, our challenge now is to manipulate this model to tip the pathologic 
progression toward decompensated AH. In summary, the chronic-plus-binge model of 
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ethanol feeding and the hybrid feeding model represent moderate and advanced ASH, 
respectively (Figure 1). These models are beginning to highlight potential differences in the 
significance of inflammation and inflammatory mediators in subclinical ASH and to 
reinforce the notion that the pathogenesis of ALD is complex and multifactorial, and stage-
dependent (Figure 1). Although we are far from achieving a “true” model which reproduces 
overt AH features, these subclinical ASH models still prove useful for comparative “omic” 
studies with AH patient samples, identification of potential molecular drivers that initiate the 
pathogenesis of ASH, and screening for therapeutic drugs targeting these molecules.
The “second or multiple hits” used experimentally include nutritional modifications, 
pharmacologic agents (e.g., Concanavalin A or CCl4, hormones, cytochrome P450 inducers, 
toll-like receptor ligands), genetic manipulation, and viral infections.52 When introducing 
these “second/multiple” hit(s), it becomes important to assess whether the hits are clinically 
relevant and whether liver pathology produced mimics clinical ALD. For example, alcohol 
feeding is used to prime and sensitize the liver for the second hit such as single injection of 
LPS or CCl4. In these models, coagulative necrosis and accompanying inflammation occur, 
but this is a primary consequence of the second hit, deviating from balloon cell degeneration 
seen in ALD. Recently, Affo et al. 53 developed a model of acute-on-chronic liver injury by 
chronically administering mice with CCl4 followed by injecting LPS, and this model has 
some features of liver inflammation observed in AH, but no alcohol was involved. 
Investigators using the “second hit” model must be cautious when interpreting the results 
since it may be difficult to determine whether the observed mechanisms are a consequence 
of the ethanol feeding or the “second hit.”
Challenges and future perspectives
AH was first described in 1961 as an acute disease that often ensues due to episodic 
excessive drinking in chronic alcoholics and is characterized by jaundice with severe clinic 
syndromes such as anorexia, nausea, upper abdominal pain, hepatomegaly and fever.54 
Today, it is generally accepted that AH is a form of acute-on-chronic liver failure in patients 
with underlying ALD. Since the mechanisms underlying AH pathogenesis remain largely 
unknown, and current therapeutic options for this severe disease are largely ineffective, there 
is an urgent need for systematic translational research to identify therapeutic targets. Many 
investigators have collaborated and started to use integrative approaches to investigate the 
pathogenesis of AH and explore the novel therapeutic targets for AH by analyzing human 
AH biopsy samples and animal models. For example, a recent collaborative study have 
compared transcriptome data from a clinically relevant chronic-plus-binge model and 
biopsy-proven AH and identified similar alterations in expression of many hepatic genes in 
this animal model and human AH samples.23 Among these genes, fat-specific protein 27 
(Fsp27)/CIDEC, which was highly upregulated in this animal model and in AH samples, 
plays an important role in promoting ASH in mice and possibly also in humans.23 In 
addition, the NIAAA released a major initiative to support four large multi-institutional 
consortia for conducting translational research on the pathogenesis of AH, identification of 
new therapeutic targets and performing clinical trials of plausible drugs for AH therapy. 
These efforts will likely enhance our understanding of AH pathogenesis and help identify 
novel therapies for AH. Despite these recent efforts on AH, many challenges remain for the 
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research and therapy of this severe disease.15 First, the current models do not fully reproduce 
all features of severe human AH, and many of these models represent subclinical ASH. The 
requisite to continue to develop the appropriate in vivo models that closely mimic human 
AH are warranted. Second, chronic ethanol feeding models in rodents that have been used 
for the last forty years have revealed therapeutic targets, and these targets may be relevant to 
early stages of ALD but not acute-on-chronic liver injury in AH. It is essential to re-examine 
these targets in chronic-plus-binge ethanol feeding models or severe “multi-hit” hybrid 
models before testing in AH patients. Third, so far, many therapeutic targets have been 
identified from the studies of human AH samples and animal models. Here, it is important to 
recognize that targets identified in mild vs. severe ASH models may have different 
functional significance, and targeting such “presumed-culprits” may yield completely 
different or even opposite outcomes as recently noted for osteopontin.25, 55 Carefully 
designed clinical trials to test these targets in AH patients are urgently needed. Finally, AH is 
a major severe form of liver disease worldwide, with no effective drugs for this disease. 
Therefore, there is an urgent need to train young hepatologists and basic/discovery scientists, 
and foster global collaborations in both clinical and basic research related to ALD, 
particularly AH.
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Figure 1. Histology, pathogenesis, and experimental models for various stages of ALD, including 
steatosis, subclinical ASH ± fibrosis, and AH
Histology and pathogenesis of steatosis, subclinical ASH with or without fibrosis, and AH 
are briefly summarized with more details in the text. Several animal models currently used 
in the field could represent the different stages of ALD. Chronic ab lib feeding of the Lieber-
DeCarli (L/D) ethanol diet is a model to study the early stage of ALD such as steatosis.56 
Several models have been used to investigate subclinical ASH with the strongest liver 
damage in western diet ab lib + iG alcohol +weekly binge,25 followed by western diet ab lib 
+ iG alcohol, 25 iG alcohol with HFD,57 L/D+ multiple binges,23 and L/D+ single 
binge.23, 49 The western diet ab lib + iG +weekly binge model recapitulates some of 
histologic and clinical features of human AH 25 and the L/D+ multiple binge model also 
partially reproduces these features but to a lesser degree.23 Models using second hits such as 
LPS or CCl4 exhibit coagulative necrosis, failing to recapitulate clinical AH features.
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Figure 2. Pathogenesis and molecular mechanisms that trigger liver failure, SIRS, and multi-
organ failure in AH
Excessive drinking in alcoholics with underlying ALD induces hepatocellular damage, 
induces systemic inflammation, and impairs liver regeneration, resulting in liver failure and 
other complications in AH.
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Figure 3. Clinical and Translational Methods in AH
Description of the step-wise process to test plausible drug targets is briefly described here. 
The method involves omics analysis to animal models, preclinical drug development 
culminating in testing drugs systematically in phase I-IV clinical trials in AH patients.
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Table 1
Molecular targets for AH: Anti-inflammatory and Hepatoprotective
Targets Potential mechanisms Beneficial effects Detrimental effects, or 
obscure functions in AH
Anti-Inflammatory targets
Steroids Broad immunosuppression. Inhibits systemic inflammation; 
Improves short-term survival rates in 
AH patents.
Increases infection; Inhibits 
liver regeneration;44 
Exacerbates neutrophilia.
Modulation of gut 
microbiome
ALD is associated with intestinal 
bacterial overgrowth and 
dysbiosis.28, 58
Probiotics improve liver functions in 
patients with ALD.59
Clinical trial using 
probiotics for the treatment 
of AH is under 
consideration.
Gut leakage-LPS-TNF-α Chronic alcohol drinking increases 
gut leakage and elevates LPS and 
TNF-α.
Inhibition of gut leakage, LPS, and 
TNF-α improves liver functions in 
animal models of ALD.
Anti-TNF-α therapy did not 
improve survival rate in AH 
patients.32 Anti-LPS trial 
and Zinc nutritional 
supplement trial for the 
treatment of AH are under 
consideration.
IL-1 inhibitor IL-1 promotes liver injury and 
inflammation in animal models. 34
Inhibition of IL-1 improves liver 
functions in animal models of ALD. 34
Anti-IL-1 trial for the 
treatment of AH is under 
consideration.
Chemokines and their 
receptors.
Human AH is associated with 
upregulation of a variety of 
chemokines and their receptors, 
which promote inflammation. 35, 53
Inhibition of various chemokines and 
their receptors ameliorates liver injury 
in animal models of ALD.
Targeting multiple 
chemokines or their 
receptors may be required 
for AH therapy because of 
chemokine receptor 
redundancy.
Heat shock protein (Hsp90) Hsp90 functions as an important 
chaperone of LPS signaling and is 
required for the production of 
proinflammatory cytokines.
Hsp90 inhibitor attenuates liver 
inflammatory and injury induced by 
LPS and alcohol in animal models. 36
Many Hsp90 inhibitors are 
currently undergoing clinical 
evaluation in various types 
of diseases. Hsp90 inhibitors 
have not been tested in AH.
Complements Activation of complements plays a 
role in promoting alcoholic liver 
injury in mice.
Inhibition of complement activation 
ameliorates chronic alcoholic liver 
injury in mice. 60
The role of complement 
activation in AH has not 
been tested.
Hepatoprotective Reagents
IL-22 Promotes hepatocyte survival and 
proliferation; Inhibits bacterial 
infection.
Ameliorates steatosis, liver injury, 
bacterial infection, kidney injury, and 
promotes liver repair.45
A clinical trial of IL-22 for 
AH is under consideration.45
Caspase inhibitors AH is associated with hepatocyte 
apoptosis.
Prevents hepatocyte apoptosis. A clinical trial using caspase 
inhibitors for the treatment 
of AH was stopped (Dr. 
Vijay Shah, personal 
communication).
HGF Promotes hepatocyte proliferation 
and survival.
Ameliorates steatosis, liver injury and 
promotes liver repair.
Promotes liver cancer cell 
proliferation.
IL-6 Promotes hepatocyte survival and 
proliferation.
Ameliorates steatosis, liver injury, and 
promotes liver repair.
Promotes inflammation and 
liver cancer cell 
proliferation; Clinical 
application is halted due to 
many side effects.
Anti-oxidants Oxidative stress plays an important 
role in the pathogenesis of ALD.
Treatment with anti-oxidants shows 
beneficial effects in animal models of 
chronic ALD and in patients with 
NASH.
Treatment with anti-oxidants 
did not improve survival rate 
in patients with severe 
AH. 48
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Table 2
Commonly used animal models for ALD
Models (References) Characteristics Mechanisms Represent features of human ALD Deficiencies
Acute binge ethanol feeding 
model. 61
• Mild elevation of 
serum ALT, AST.
• Low levels of liver 
inflammation with 
a decrease in 
hepatic 
macrophages.
• Requires stomach 
gavage.
• Damages 
hepatocyte 
mitochondrial 
functions and 
produces 
oxidative 
stress.
• Represent 
mild acute 
changes: 
transient 
endotoxemia 
and fatty 
liver.
• Does not 
produce chronic 
ALD process.
Chronic Ad libitum ethanol 
feeding.56
• Mild elevation of 
serum ALT, AST.
• Low levels of liver 
inflammation with 
an increase in 
macrophages but 
not neutrophils.
• Easy to perform.
• Increases gut 
permeability 
and activates 
LPS-TLR4-
Kupffer cells.
• Damages 
hepatocyte 
mitochondrial 
functions and 
produces 
oxidative 
stress.
• Represents 
early stages 
of and mild 
chronic 
human ALD.
• Useful for the 
study of ALD 
steatosis and 
macrophage 
activation.
• Only produces 
fatty liver but 
not 
hepatocellular 
death, 
inflammation, or 
fibrosis.
Intragastric chronic ethanol 
feeding. 57
• Moderate elevation 
of serum ALT, 
AST.
• Moderate liver 
inflammation with 
an increase in 
macrophages but 
low levels of 
neutrophils.
• Require surgical 
skills.
• Severe 
mitochondrial 
GSH 
depletion.
• Accentuated 
ER, 
mitochondrial, 
and lysosomal 
stress.
• Defective 
AMPK 
pathway.
• Dysbiosis and 
bacterial 
translocation.
• M1 
macrophage 
activation.
• Achieves 
heavy alcohol 
intake and 
sustained 
blood alcohol 
levels as seen 
in ALD 
patients.
• Represents 
moderate 
chronic 
human ALD.
• Useful for the 
study of ALD 
steatosis, 
macrophage 
activation, 
and, mild 
fibrosis.
• Advanced 
cirrhosis only 
combined with 
iron 
supplementation.
• Does not 
produce AH.
Chronic-plus-binge feeding 
model.23, 49
• Moderate and 
transient elevation 
of serum ALT, 
AST.
• Moderate and 
transient liver 
inflammation with 
neutrophils.
• Requires stomach 
gavage.
• Increases 
hepatic 
neutrophil 
infiltration 
induces liver 
injury.
• Damages 
hepatocyte 
mitochondrial 
functions and 
produces 
oxidative 
stress.
• Useful for the 
study of 
transient 
neutrophil 
infiltration 
and recovery 
from it.
• Does not 
produce 
sustained 
neutrophil 
infiltration.
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Models (References) Characteristics Mechanisms Represent features of human ALD Deficiencies
HFD-plus-binge ethanol model.24 • Significant 
elevation of serum 
ALT and AST.
• Significant liver 
inflammation with 
an increase in 
neutrophils.
• Mild liver fibrosis.
• Requires stomach 
gavage.
• Damages 
hepatocyte 
mitochondrial 
functions.
• Promotes 
hepatic 
neutrophil 
infiltration and 
induces acute 
steatohepatitis.
• Represents a 
model to 
study of the 
interaction 
between 
obesity and 
binge 
drinking on 
acute 
steatohepatitis
• Advanced 
fibrosis is not 
produced.
• No clinical 
features of AH 
are produced.
Hybrid model with Western diet 
ad lib plus intragastric ethanol 
and binge. 25
• Significant 
elevation of serum 
ALT, AST, bile 
acids.
• Ballooned cell 
degeneration of 
hepatocytes.
• Intense 
inflammation 
shifting from M1 
macrophages to 
intense neutrophils 
by binge.
• Moderate liver 
fibrosis.
• Splenomegaly, 
hypoalbuminemia, 
hyperbilirubinemia.
• Ductular reaction.
• Require surgical 
skills.
• A shift from 
M1 
macrophage 
inflammation 
to neutrophil 
infiltration by 
repeated 
binge.
• Macrophage 
depletion or 
dysfunction by 
repeated 
binge.
• Enhanced 
bacterial 
translocation.
• Represents 
moderate/
severe human 
AH.
• Useful for the 
study of AH 
steatosis, 
neutrophil 
infiltration, 
macrophage 
activation, 
mild fibrosis.
• Cirrhosis and 
de-compensation 
are not 
produced.
“Second hit” or “Multiple hits” 
model.52
• Moderate to 
significant 
elevation of serum 
ALT, AST and liver 
inflammation 
dependent on 
“second hit”.
• Chronic 
ethanol 
feeding 
increases 
susceptibility 
of livers to 
second or 
multiple 
hit(s)-induced 
liver injury 
and 
inflammation.
• Depends on 
the nature of 
the second or 
multiple hits.
• Risk of 
producing 
primary injury 
from the second 
hit, deviating 
from natural 
ALD pathology.
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